# Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease

> **NCT06732180** · PHASE1 · RECRUITING · sponsor: **Gain Therapeutics, Inc.** · enrollment: 20 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** GT-02287

## Key facts

- **NCT ID:** NCT06732180
- **Lead sponsor:** Gain Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-21
- **Primary completion:** 2025-11-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06732180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06732180, "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06732180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*